局限期小细胞肺癌预防性脑照射后脑转移相关危险因素分析

doi:10.3760/cma.j.cn113030-20210129-00049

摘要
图/表
参考文献(40)
相关文章 (15)
点击分布统计
下载分布统计

全文: PDF (0 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS) 背景资料

摘要小细胞肺癌具有易复发和转移的生物学特点,脑是小细胞肺癌肺外转移的好发部位。局限期小细胞肺癌患者行预防性脑照射(PCI)能够有效降低脑转移的发生率,延长总生存期。但是在PCI后仍有近 1/3的患者发生脑转移。本文对PCI后脑转移的危险因素进行综述,目的在于判断何种局限期小细胞肺癌亚组患者能够从PCI中获益,从而为PCI的临床应用提供参考。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	李明旭
	胡松柳

关键词 ：癌,小细胞肺, 预防性脑照射, 脑转移, 危险因素

Abstract：Small cell lung cancer (SCLC) has the biological characteristics of high recurrence and metastasis. The brain is the common site of SCLC extrapulmonary metastasis. Prophylactic cranial irradiation (PCI) can effectively reduce the incidence of brain metastasis and prolong the overall survival of patients with limited SCLC. Nevertheless, nearly one third of patients develop brain metastases after PCI. This article reviews the risk factors of brain metastasis after PCI, aiming to determine which subgroup of patients with limited SCLC can benefit from PCI and provide reference for the clinical application of PCI.

Key words： Neoplasm, small cell lung Prophylactic cranial irradiation Brain metastasis Risk factor

收稿日期: 2021-01-29

基金资助:国家癌症中心攀登基金(NCC201808B015);中国医疗手牵手工程委员会-北京医学奖励基金会基金(YXJL-2020-0961-0159)

通讯作者: 胡松柳,Email:husongliu@126.com

引用本文:

李明旭,胡松柳. 局限期小细胞肺癌预防性脑照射后脑转移相关危险因素分析[J]. 中华放射肿瘤学杂志, 2022, 31(4): 395-399.

Li Mingxu,Hu Songliu. Analysis of risk factors associated with brain metastasis of limited small cell lung cancer after prophylactic cranial irradiation[J]. Chinese Journal of Radiation Oncology, 2022, 31(4): 395-399.

链接本文:

http://journal12.magtechjournal.com/Jweb_fszlx/CN/10.3760/cma.j.cn113030-20210129-00049 或 http://journal12.magtechjournal.com/Jweb_fszlx/CN/Y2022/V31/I4/395

[1] Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years:analysis of the surveillance, epidemiologic, and end results database[J]. J Clin Oncol,2006,24(28):4539-4544. DOI:10.1200/JCO.2005.04.4859.
[2] Aupérin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. prophylactic cranial irradiation overview collaborative group[J]. N Engl J Med, 1999, 341(7):476-484. DOI:10.1056/NEJM199908123410703.
[3] Brink I, Schumacher T, Mix M, et al. Impact of^[18F]FDG-PET on the primary staging of small-cell lung cancer[J]. Eur J Nucl Med Mol Imaging,2004,31(12):1614-1620. DOI:10.1007/s00259-004-1606-x.
[4] Kishida Y, Seki S, Yoshikawa T, et al. Performance comparison between (18) F-FDG pet/CT plus brain MRI and conventional staging plus brain MRI in staging of small cell lung carcinoma[J]. AJR Am J Roentgenol, 2018, 211(1):185-192. DOI:10.2214/AJR.17.18935.
[5] Martucci F, Pascale M, Valli MC, et al. Impact of (18) F-FDG PET/CT in staging patients with small cell lung cancer:A systematic review and meta-analysis[J]. Front Med (Lausanne), 2019, 6:336. DOI:10.3389/fmed.2019.00336.
[6] 刘璇, 周宗玫, 肖泽芬, 等. 现代诊疗技术下脑预防照射在局限期小细胞肺癌中的疗效分析[J]. 中华放射肿瘤学杂志, 2021, 30(02):114-119. DOI:10.3760/cma.j.cn113030-20200809-00407.
Liu X, Zhou ZM, Xiao ZF, et al. Long-term outcomes and failure patterns of prophylactic cranial irradiation in limited-stage small cell lung cancer patients managed with modern chemoradiotherapy and diagnostic methods[J]. Chin J Radiat Oncol,2021,30(2):114-119. DOI:10.3760/cma.j.cn113030-20200809-00407.
[7] Farooqi AS, Holliday EB, Allen PK, et al. Prophylactic cranial irradiation after definitive chemoradiotherapy for limited-stage small cell lung cancer:do all patients benefit?[J]. Radiother Oncol, 2017, 122(2):307-312. DOI:10.1016/j.radonc.2016.11.012.
[8] Kim TG, Pyo H, Ahn YC, et al. Role of prophylactic cranial irradiation for elderly patients with limited-disease small-cell lung cancer:inverse probability of treatment weighting using propensity score[J]. J Radiat Res, 2019, 60(5):630-638. DOI:10.1093/jrr/rrz040.
[9] Rule WG, Foster NR, Meyers JP, et al. Prophylactic cranial irradiation in elderly patients with small cell lung cancer:findings from a north central cancer treatment group pooled analysis[J]. J Geriatr Oncol, 2015, 6(2):119-126. DOI:10.1016/j.jgo.2014.11.002.
[10] Eaton BR, Kim S, Marcus DM, et al. Effect of prophylactic cranial irradiation on survival in elderly patients with limited-stage small cell lung cancer[J]. Cancer, 2013, 119(21):3753-3760. DOI:10.1002/cncr.28267.
[11] Guo D, Jing W, Zhu H, et al. Clinical value of carcinoembryonic antigen for predicting the incidence of brain metastases and survival in small cell lung cancer patients treated with prophylactic cranial irradiation[J]. Cancer Manag Res, 2018, 10:3199-3205. DOI:10.2147/CMAR.S175043.
[12] Levy A, Le Péchoux C, Mistry H, et al. Prophylactic cranial irradiation for limited-stage small-cell lung cancer patients:secondary findings from the prospective randomized phase 3 CONVERT trial[J]. J Thorac Oncol, 2019, 14(2):294-297. DOI:10.1016/j.jtho.2018.09.019.
[13] Kou P, Wang H, Yang D, et al. Application of prophylactic cranial irradiation in limited-stage small-cell lung cancer:which patients could benefit?[J]. Future Oncol, 2019, 15(1):3237-3245. DOI:10.2217/fon-2018-0481.
[14] Zeng H, Xie P, Meng X, et al. Risk factors for brain metastases after prophylactic cranial irradiation in small cell lung cancer[J]. Sci Rep, 2017, 7:42743. DOI:10.1038/srep42743.
[15] Hu X, Bao Y, Xu YJ, et al. Final report of a prospective randomized study on thoracic radiotherapy target volume for limited-stage small cell lung cancer with radiation dosimetric analyses[J]. Cancer, 2020, 126(4):840-849. DOI:10.1002/cncr.32586.
[16] Le Péchoux C, Dunant A, Senan S, et al. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01):a randomised clinical trial[J]. Lancet Oncol, 2009, 10(5):467-474. DOI:10.1016/S1470-2045(09)70101-9.
[17] Sas-Korczyńska B, Korzeniowski S, Wójcik E. Comparison of the effectiveness of"late" and"early" prophylactic cranial irradiation in patients with limited-stage small cell lung cancer[J]. Strahlenther Onkol, 2010, 186(6):315-319. DOI:10.1007/s00066-010-2088-3.
[18] 霍东杰, 陆艳荣, 王海峰, 等. 预防性全脑照射及其不同介入时机对局限期小细胞肺癌预后的影响[J]. 天津医药, 2017, 45(12):1261-1265. DOI:10.11958/20170823.
Huo DJ, Lu YR, Wang HF,et al. Effects of prophylactic cranial irradiation and its different optional times on prognosis of limited-stage small cell lung cancer[J]. Tianjin Med J,2017,45(12):1261-1265. DOI:10.11958/20170823.
[19] Qiu G, DU X, Zhou X, et al. Prophylactic cranial irradiation in 399 patients with limited-stage small cell lung cancer[J]. Oncol Lett, 2016, 11(4):2654-2660. DOI:10.3892/ol.2016.4231.
[20] Xu J, Yang H, Fu X, et al. Prophylactic cranial irradiation for patients with surgically resected small cell lung cancer[J]. J Thorac Oncol, 2017, 12(2):347-353. DOI:10.1016/j.jtho.2016.09.133.
[21] Zhu H, Bi Y, Han A, et al. Risk factors for brain metastases in completely resected small cell lung cancer:a retrospective study to identify patients most likely to benefit from prophylactic cranial irradiation[J]. Radiat Oncol, 2014, 9:216. DOI:10.1186/1748-717X-9-216.
[22] Uprety D, Arjyal L, Vallatharasu Y, et al. Utilization of surgery and its impact on survival in patients with early stage small-cell lung cancer in the united states[J]. Clin Lung Cancer, 2020, 21(2):186-193.e2. DOI:10.1016/j.cllc.2019.07.013.
[23] Manapov F, Klöcking S, Niyazi M, et al. Primary tumor response to chemoradiotherapy in limited-disease small-cell lung cancer correlates with duration of brain-metastasis free survival[J]. J Neurooncol, 2012, 109(2):309-314. DOI:10.1007/s11060-012-0894-4.
[24] 裘国勤, 周霞, 包婺安, 等. 局限期SCLC预防性脑照射后脑转移的危险因素分析[J]. 中华放射肿瘤学杂志, 2016, 25(10):1062-1065. DOI:10.3760/cma.j.issn.1004-4221.2016.10.008.
Qiu GQ, Zhou X, Bao WA, et al. An analysis of risk factors for brain metastases after prophylactic cranial irradiation for limited-stage small-cell lung cancer[J]. Chin J Radiat Oncol,2016,25(10):1062-1065. DOI:10.3760/cma.j.issn.1004-4221.2016.10.008.
[25] Farris MK, Wheless WH, Hughes RT, et al. Limited-stage small cell lung cancer:is prophylactic cranial irradiation necessary?[J]. Pract Radiat Oncol, 2019, 9(6):e599-e607. DOI:10.1016/j.prro.2019.06.014.
[26] Dong A, Zhang J, Chen X, et al. Diagnostic value of proGRP for small cell lung cancer in different stages[J]. J Thorac Dis, 2019, 11(4):1182-1189. DOI:10.21037/jtd.2019.04.29.
[27] Li M, Han D, Wang W, et al. Decline in serum progastrin-releasing peptide predicts the response of patients with small cell lung cancer to chemotherapy[J]. Oncol Lett, 2020, 20(6):301. DOI:10.3892/ol.2020.12164.
[28] Yonemori K, Sumi M, Fujimoto N, et al. Pro-gastrin-releasing peptide as a factor predicting the incidence of brain metastasis in patients with small cell lung carcinoma with limited disease receiving prophylactic cranial irradiation[J]. Cancer, 2005, 104(4):811-816. DOI:10.1002/cncr.21238.
[29] Guo WL, He ZY, Chen Y, et al. Clinical features of brain metastases in small cell lung cancer:an implication for hippocampal sparing whole brain radiation therapy[J]. Transl Oncol, 2017, 10(1):54-58. DOI:10.1016/j.tranon.2016.11.002.
[30] Chammah SE, Allenbach G, Jumeau R, et al. Impact of prophylactic cranial irradiation and hippocampal sparing on (18) F-FDG brain metabolism in small cell lung cancer patients[J]. Radiother Oncol, 2021, 158:200-206. DOI:10.1016/j.radonc.2021.02.016.
[31] Lin SY, Yang CC, Wu YM, et al. Evaluating the impact of hippocampal sparing during whole brain radiotherapy on neurocognitive functions:A preliminary report of a prospective phase Ⅱ study[J]. Biomed J, 2015, 38(5):439-449. DOI:10.4103/2319-4170.157440.
[32] Tsai PF, Yang CC, Chuang CC, et al. Hippocampal dosimetry correlates with the change in neurocognitive function after hippocampal sparing during whole brain radiotherapy:a prospective study[J]. Radiat Oncol, 2015, 10:253. DOI:10.1186/s13014-015-0562-x.
[33] Gondi V, Tolakanahalli R, Mehta MP, et al. Hippocampal-sparing whole-brain radiotherapy:a"how-to" technique using helical tomotherapy and linear accelerator-based intensity-modulated radiotherapy[J]. Int J Radiat Oncol Biol Phys, 2010, 78(4):1244-1252. DOI:10.1016/j.ijrobp.2010.01.039.
[34] Redmond KJ, Hales RK, Anderson-Keightly H, et al. Prospective study of hippocampal-sparing prophylactic cranial irradiation in limited-stage small cell lung cancer[J]. Int J Radiat Oncol Biol Phys, 2017, 98(3):603-611. DOI:10.1016/j.ijrobp.2017.03.009.
[35] Cho Y, Lee J, Lee IJ, et al. Intracranial failure after hippocampal-avoidance prophylactic cranial irradiation in limited-stage small-cell lung cancer patients[J]. Sci Rep, 2021, 11(1):7435. DOI:10.1038/s41598-021-86851-6.
[36] Harth S, Abo-Madyan Y, Zheng L, et al. Estimation of intracranial failure risk following hippocampal-sparing whole brain radiotherapy[J]. Radiother Oncol, 2013, 109(1):152-158. DOI:10.1016/j.radonc.2013.09.009.
[37] Belderbos J, De Ruysscher D, De Jaeger K, et al. Phase 3 randomized trial of prophylactic cranial irradiation with or without hippocampus avoidance in SCLC (NCT01780675)[J]. J Thorac Oncol, 2021, 16(5):840-849. DOI:10.1016/j.jtho.2020.12.024.
[38] 陈维领, 李鑫, 陈杼君, 等. 伊立替康联合铂类一线化疗对小细胞肺癌脑转移的影响[J]. 第三军医大学学报, 2020, 42(5):487-492. DOI:10.16016/j.1000-5404.201910211.
Chen WL, Li X, Chen ZJ,et al. Effect of irinotecan combined with platinum first-line chemoth-erapy on brain metastasis of small cell lung cancer[J]. J Third Military Med Univers,2020,42(5):487-492. DOI:10.16016/j.1000-5404.201910211.
[39] Zheng Y, Wang L, Zhao W, et al. Risk factors for brain metastasis in patients with small cell lung cancer without prophylactic cranial irradiation[J]. Strahlenther Onkol, 2018, 194(12):1152-1162. DOI:10.1007/s00066-018-1362-7.
[40] Pezzi TA, Fang P, Gjyshi O, et al. Rates of overall survival and intracranial control in the magnetic resonance imaging era for patients with limited-stage small cell lung cancer with and without prophylactic cranial irradiation[J]. JAMA Netw Open, 2020, 3(4):e201929. DOI:10.1001/jamanetworkopen.2020.1929.